Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBM588 in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
NCT03922035Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jun 2019
- Primary completion
- Feb 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in hematopoietic and lymphoid cell neoplasm comparing Arm I (CBM588) with Arm II (standard of care) (2 arms). Primary endpoints: Incidence of adverse events at 100 days and Feasibility of CBM588. Started Jun 2019; status: active, not recruiting.
02
Drugs
clostridium butyricum
03
Conditions
hematopoietic and lymphoid cell neoplasm
Beyond the preview
Go deeper on NCT03922035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922035.